Accueil   Diary - News   All news THERANEXUS: INCLUSION OF LAST PATIENT IN PHASE II TRIAL FOR THN102 IN PARKINSON’S PATIENTS

THERANEXUS: INCLUSION OF LAST PATIENT IN PHASE II TRIAL FOR THN102 IN PARKINSON’S PATIENTS

 

 

  • This trial conducted in Europe and the United States evaluates the tolerance and efficacy of THN102 on non-motor symptoms in Parkinson's disease patients.
  • Trial results expected in Q1 2020

 

 

Lyon, 24 September 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, recently achieved a new milestone by recruiting the last patient with Parkinson’s disease to its Phase II clinical trial which aims to evaluate the tolerance and efficacy of its drug candidate THN102 on non-motor symptoms of the disease.

 


Parkinson’s disease patients with excessive daytime sleepiness have been recruited across Europe and the United States. The trial’s primary endpoint is tolerance to the drug candidate THN102; the secondary efficacy endpoints concern a number of debilitating non-motor symptoms of the disease and include an assessment of sleepiness, attention and cognition. The study is a double-blind, placebo-controlled, crossover trial with a one-week washout period between each successive two-week period of the following treatments in random order: THN102 200mg modafinil/2mg flecainide, THN102 200mg modafinil/18mg flecainide, or a placebo.

 

Read the press release